Rhumbline Advisers Rigel Pharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$1.12 - $1.57 $9,061 - $12,702	8,091 Added 3.52%	237,943 $352,000
Q4 2023 Feb 08, 2024	BUY	$0.72 - $1.56 $905 - $1,960	1,257 Added 0.55%	229,852 $333,000
Q3 2023 Nov 09, 2023	BUY	$1.07 - $1.39 $765 - $993	715 Added 0.31%	228,595 $246,000
Q2 2023 Aug 08, 2023	BUY	$1.12 - $1.82 $4,480 - $7,280	4,000 Added 1.79%	227,880 $293,000
Q1 2023 May 11, 2023	BUY	$1.25 - $2.0 $7,012 - $11,220	5,610 Added 2.57%	223,880 $296,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $3,530 - $62,713	5,270 Added 2.47%	218,270 $327,000
Q3 2022 Nov 10, 2022	BUY	$1.1 - $12.2 $25,117 - $278,574	22,834 Added 12.01%	213,000 $251,000
Q2 2022 Aug 11, 2022	BUY	$0.67 - $3.19 $4,568 - $21,752	6,819 Added 3.72%	190,166 $215,000
Q1 2022 May 12, 2022	BUY	$2.22 - $3.45 $2,461 - $3,826	1,109 Added 0.61%	183,347 $548,000
Q4 2021 Feb 10, 2022	SELL	$2.36 - $3.57 $8,319 - $12,584	-3,525 Reduced 1.9%	182,238 $483,000
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $14,777 - $18,999	4,222 Added 2.33%	185,763 $674,000
Q2 2021 Aug 05, 2021	SELL	$3.09 - $4.54 $49,097 - $72,136	-15,889 Reduced 8.05%	181,541 $788,000
Q1 2021 May 06, 2021	SELL	$3.35 - $4.93 $43,684 - $64,287	-13,040 Reduced 6.2%	197,430 $675,000
Q4 2020 Feb 10, 2021	BUY	$2.35 - $3.74 $28,529 - $45,403	12,140 Added 6.12%	210,470 $737,000
Q3 2020 Nov 12, 2020	SELL	$1.78 - $4.13 $49,279 - $114,339	-27,685 Reduced 12.25%	198,330 $476,000
Q2 2020 Aug 13, 2020	SELL	$1.41 - $2.05 $6,952 - $10,108	-4,931 Reduced 2.14%	226,015 $414,000
Q1 2020 May 06, 2020	SELL	$1.27 - $3.0 $2,540 - $6,000	-2,000 Reduced 0.86%	230,946 $360,000
Q4 2019 Feb 05, 2020	BUY	$1.6 - $2.43 $6,235 - $9,469	3,897 Added 1.7%	232,946 $499,000
Q3 2019 Oct 23, 2019	BUY	$1.63 - $2.62 $964 - $1,551	592 Added 0.26%	229,049 $428,000
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $30,621 - $39,564	15,159 Added 7.11%	228,457 $596,000
Q1 2019 May 01, 2019	SELL	$2.0 - $2.65 $9,664 - $12,804	-4,832 Reduced 2.22%	213,298 $548,000
Q4 2018 Jan 31, 2019	BUY	$2.08 - $3.36 $148,699 - $240,206	71,490 Added 48.75%	218,130 $502,000
Q3 2018 Nov 07, 2018	SELL	$2.6 - $3.59 $23,075 - $31,861	-8,875 Reduced 5.71%	146,640 $471,000
Q2 2018 Aug 06, 2018	BUY	$2.83 - $4.11 $61,538 - $89,371	21,745 Added 16.26%	155,515 $440,000
Q1 2018 May 02, 2018	BUY	$3.54 - $4.54 $54,799 - $70,279	15,480 Added 13.09%	133,770 $474,000
Q4 2017 Feb 09, 2018	SELL	$3.23 - $4.3 $76,208 - $101,454	-23,594 Reduced 16.63%	118,290 $459,000
Q3 2017 Nov 06, 2017	BUY	$2.18 - $2.57 $309,307 - $364,641	141,884	141,884 $360,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account